Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
暂无分享,去创建一个
[1] F. V. Lente,et al. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] U. Stenman,et al. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. , 1997, The Journal of urology.
[3] A. Partin,et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.
[4] B. Lacour,et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. , 1995, Clinical chemistry.
[5] W. Heston. Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen. , 1995, Clinical chemistry.
[6] U. Stenman,et al. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. , 1995, Clinical chemistry.
[7] A. Deblasio,et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.
[8] P. Kantoff,et al. Detection of circulating tumor cells in men with localized prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Schwartz,et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.
[10] M. Benson,et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. , 1994, Urology.
[11] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[12] A. Partin,et al. Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. , 1993, The Journal of urology.
[13] Dale McLerran,et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.
[14] P. Humphrey,et al. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate‐specific antigen levels , 1993, Cancer.
[15] W. Fair,et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.
[16] C. Croce,et al. Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.
[17] J. Epstein,et al. Evaluation of Radical Prostatectomy Specimens: A Comparative Analysis of Sampling Methods , 1992, The American journal of surgical pathology.
[18] M. Benson,et al. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. , 1995, The Journal of urology.